Study declares clear winner in diabetes drug comparison

Metformin reduces the relative risk of a diabetes patient dying from heart disease by 30 to 40% compared to its closest rival, sulfonylurea.

This is the major finding from a systematic review and meta-analysis of 204 studies involving more than 1.4 million people.

Designed to assess the comparative, not absolute individual, benefits and risks of more than a dozen FDA-approved drugs